AR105836A1 - Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk - Google Patents
Compuestos y composiciones útiles para tratar trastornos relacionados con ntrkInfo
- Publication number
- AR105836A1 AR105836A1 ARP160102616A ARP160102616A AR105836A1 AR 105836 A1 AR105836 A1 AR 105836A1 AR P160102616 A ARP160102616 A AR P160102616A AR P160102616 A ARP160102616 A AR P160102616A AR 105836 A1 AR105836 A1 AR 105836A1
- Authority
- AR
- Argentina
- Prior art keywords
- cycloalkyl
- alkylene
- heterocyclyl
- heteroalkyl
- haloalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562210264P | 2015-08-26 | 2015-08-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR105836A1 true AR105836A1 (es) | 2017-11-15 |
Family
ID=56896780
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP160102616A AR105836A1 (es) | 2015-08-26 | 2016-08-26 | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10017512B2 (https=) |
| EP (1) | EP3341374A1 (https=) |
| JP (1) | JP6877407B2 (https=) |
| KR (1) | KR20180043810A (https=) |
| CN (1) | CN108137607B (https=) |
| AR (1) | AR105836A1 (https=) |
| AU (1) | AU2016311426B2 (https=) |
| BR (1) | BR112018003588A2 (https=) |
| CA (1) | CA2995997A1 (https=) |
| HK (1) | HK1255330A1 (https=) |
| IL (1) | IL257702A (https=) |
| MX (1) | MX2018002407A (https=) |
| PH (1) | PH12018500397A1 (https=) |
| RU (1) | RU2744974C2 (https=) |
| TW (1) | TW201713665A (https=) |
| WO (1) | WO2017035354A1 (https=) |
| ZA (1) | ZA201801881B (https=) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| US11040979B2 (en) | 2017-03-31 | 2021-06-22 | Blueprint Medicines Corporation | Substituted pyrrolo[1,2-b]pyridazines for treating disorders related to KIT and PDGFR |
| DK3674307T3 (da) | 2017-08-23 | 2023-09-11 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Makrocyklus indeholdende aminopyrazol og pyrimidin og farmaceutisk sammensætning og anvendelse deraf |
| WO2019079649A1 (en) | 2017-10-18 | 2019-04-25 | Blueprint Medicines Corporation | SUBSTITUTED PYRROLOPYRIDINES AS INHIBITORS OF ACTIVIN RECEPTOR-RELATED KINASE |
| WO2019152982A1 (en) * | 2018-02-05 | 2019-08-08 | Shenzhen Ionova Life Science Co., Ltd. | Heterobicyclic compounds as ep4 antagonists |
| BR112020019399A2 (pt) * | 2018-03-28 | 2021-01-05 | Fochon Pharmaceuticals, Ltd. | Compostos macrocíclicos como inibidores de trk quinases |
| SI3773589T1 (sl) | 2018-04-03 | 2024-03-29 | Blueprint Medicines Corporation | Inhibitor RET za uporabo pri zdravljenju raka, ki ima RET spremembo |
| MX2021010173A (es) * | 2019-02-27 | 2021-12-10 | Ferro Therapeutics Inc | Compuestos con actividad inductora de ferroptosis y métodos de uso. |
| WO2020210669A1 (en) | 2019-04-12 | 2020-10-15 | Blueprint Medicines Corporation | Crystalline forms of (s)-1-(4-fluorophenyl)-1-(2-(4-(6-(1-methyl-1h-pyrazol-4-yl)pyrrolo[2,1-f][1,2,4]triazin-4-yl)piperazinyl)-pyrimidin-5-yl)ethan-1-amine and methods of making |
| EP4065585B1 (en) * | 2019-11-25 | 2025-08-20 | Alkermes, Inc. | Substituted macrocyclic compounds and related methods of treatment |
| JP2023527412A (ja) | 2020-05-29 | 2023-06-28 | ブループリント メディシンズ コーポレイション | プラルセチニブの固体形態 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN113408945B (zh) * | 2021-07-15 | 2023-03-24 | 广西中烟工业有限责任公司 | 一种烤烟纯度的检测方法、装置、电子设备及存储介质 |
Family Cites Families (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6251911B1 (en) * | 1996-10-02 | 2001-06-26 | Novartis Ag | Pyrimidine derivatives and processes for the preparation thereof |
| PT1537116E (pt) | 2002-09-04 | 2010-09-03 | Schering Corp | Pirazolopirimidinas adequadas para o tratamento de doenças cancerosas |
| US7329662B2 (en) | 2003-10-03 | 2008-02-12 | Hoffmann-La Roche Inc. | Pyrazolo-pyridine |
| TWI378934B (en) * | 2004-04-02 | 2012-12-11 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
| WO2005117909A2 (en) * | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| WO2009032703A1 (en) * | 2007-08-28 | 2009-03-12 | Irm Llc | 2- (het) arylamino-6-aminopyridine derivatives and fused forms thereof as anaplastic lymphoma kinase inhibitors |
| AR074052A1 (es) | 2008-10-22 | 2010-12-22 | Array Biopharma Inc | Compuestos pirazolo{1,5-a}pirimidina sustituida como inhibidores de trk cinasa |
| AR077468A1 (es) | 2009-07-09 | 2011-08-31 | Array Biopharma Inc | Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa |
| EP2566866A1 (en) * | 2010-05-05 | 2013-03-13 | Vertex Pharmaceuticals Incorporated | 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors |
| US8637516B2 (en) | 2010-09-09 | 2014-01-28 | Irm Llc | Compounds and compositions as TRK inhibitors |
| WO2012034095A1 (en) | 2010-09-09 | 2012-03-15 | Irm Llc | Compounds and compositions as trk inhibitors |
| CN102241678B (zh) | 2011-04-26 | 2014-10-29 | 辽宁利锋科技开发有限公司 | 含有脂环结构化合物的抗肿瘤作用与应用 |
| SMT202100451T1 (it) | 2012-07-11 | 2021-09-14 | Blueprint Medicines Corp | Inibitori del recettore di crescita dei fibroblasti |
| CA2882759C (en) * | 2012-08-31 | 2018-11-20 | The Regents Of The University Of Colorado | Detection of the ntrk1-mprip gene fusion for cancer diagnosis |
| KR20150072412A (ko) | 2012-10-05 | 2015-06-29 | 리겔 파마슈티칼스, 인크. | Gdf-8 억제제 |
| AU2013337277B2 (en) | 2012-11-05 | 2018-03-08 | Foundation Medicine, Inc. | Novel NTRK1 fusion molecules and uses thereof |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| JP2016506944A (ja) * | 2013-02-01 | 2016-03-07 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換ピラゾロピリミジニルアミノ−インダゾール |
| CN103965199B (zh) | 2013-02-02 | 2017-07-07 | 广东东阳光药业有限公司 | 一种芳杂环化合物、包含它的药物组合物及其用途 |
| MX2015010700A (es) | 2013-02-21 | 2017-01-23 | Calitor Sciences Llc | Compuestos heteroaromaticos como moduladores de la p13 cinasa. |
| WO2014139326A1 (en) | 2013-03-13 | 2014-09-18 | Genentech, Inc. | Pyrazolo compounds and uses thereof |
| WO2014160521A1 (en) | 2013-03-15 | 2014-10-02 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| GB2515785A (en) * | 2013-07-03 | 2015-01-07 | Redx Pharma Ltd | Compounds |
| MX365614B (es) | 2013-10-17 | 2019-06-07 | Blueprint Medicines Corp | Composiciones utiles para tratar trastornos relacionados con kit. |
| US9334263B2 (en) | 2013-10-17 | 2016-05-10 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2928042C (en) | 2013-10-25 | 2022-05-10 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2015108992A1 (en) | 2014-01-15 | 2015-07-23 | Blueprint Medicines Corporation | Heterobicyclic compounds and their use as fgfr4 receptor inhibitors |
| CN106536507B (zh) | 2014-04-08 | 2020-04-07 | 里格尔药品股份有限公司 | 作为TGF-β抑制剂的2,3-二取代的吡啶化合物及其使用方法 |
| WO2016022569A1 (en) | 2014-08-04 | 2016-02-11 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CA2971024C (en) | 2014-12-15 | 2023-09-26 | Handok Inc. | Fused ring heteroaryl compounds and their use as trk inhibitors |
| US10202365B2 (en) | 2015-02-06 | 2019-02-12 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as RET inhibitors |
| CN107531666A (zh) | 2015-02-20 | 2018-01-02 | 里格尔药品股份有限公司 | Gdf‑8抑制剂 |
| WO2017019442A1 (en) | 2015-07-24 | 2017-02-02 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to kit and pdgfr |
| AU2016311426B2 (en) | 2015-08-26 | 2021-05-20 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to NTRK |
| PL3371171T3 (pl) | 2015-11-02 | 2024-03-25 | Blueprint Medicines Corporation | Inhibitory RET |
| MX2018006195A (es) | 2015-11-19 | 2018-09-05 | Blueprint Medicines Corp | Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk. |
| TW201738228A (zh) | 2016-03-17 | 2017-11-01 | 藍圖醫藥公司 | Ｒｅｔ之抑制劑 |
| SG11201808907PA (en) | 2016-04-15 | 2018-11-29 | Blueprint Medicines Corp | Inhibitors of activin receptor-like kinase |
| US10227329B2 (en) | 2016-07-22 | 2019-03-12 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018022761A1 (en) | 2016-07-27 | 2018-02-01 | Blueprint Medicines Corporation | Substituted cyclopentane-amides for treating disorders related to ret |
| WO2018049233A1 (en) | 2016-09-08 | 2018-03-15 | Nicolas Stransky | Inhibitors of the fibroblast growth factor receptor in combination with cyclin-dependent kinase inhibitors |
| CN107844168B (zh) | 2017-11-23 | 2020-12-01 | 英业达科技有限公司 | 主板组件及其卡扣装置 |
-
2016
- 2016-08-25 AU AU2016311426A patent/AU2016311426B2/en not_active Expired - Fee Related
- 2016-08-25 CN CN201680060799.0A patent/CN108137607B/zh not_active Expired - Fee Related
- 2016-08-25 MX MX2018002407A patent/MX2018002407A/es unknown
- 2016-08-25 HK HK18114466.6A patent/HK1255330A1/zh unknown
- 2016-08-25 CA CA2995997A patent/CA2995997A1/en not_active Abandoned
- 2016-08-25 EP EP16763630.7A patent/EP3341374A1/en not_active Withdrawn
- 2016-08-25 RU RU2018110379A patent/RU2744974C2/ru active
- 2016-08-25 BR BR112018003588A patent/BR112018003588A2/pt not_active IP Right Cessation
- 2016-08-25 WO PCT/US2016/048698 patent/WO2017035354A1/en not_active Ceased
- 2016-08-25 JP JP2018510406A patent/JP6877407B2/ja not_active Expired - Fee Related
- 2016-08-25 KR KR1020187008146A patent/KR20180043810A/ko not_active Withdrawn
- 2016-08-26 US US15/248,207 patent/US10017512B2/en active Active
- 2016-08-26 TW TW105127561A patent/TW201713665A/zh unknown
- 2016-08-26 AR ARP160102616A patent/AR105836A1/es unknown
-
2018
- 2018-02-22 PH PH12018500397A patent/PH12018500397A1/en unknown
- 2018-02-25 IL IL257702A patent/IL257702A/en unknown
- 2018-03-20 ZA ZA2018/01881A patent/ZA201801881B/en unknown
- 2018-07-03 US US16/027,166 patent/US11046697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| KR20180043810A (ko) | 2018-04-30 |
| PH12018500397A1 (en) | 2018-08-29 |
| AU2016311426A1 (en) | 2018-04-05 |
| US10017512B2 (en) | 2018-07-10 |
| RU2744974C2 (ru) | 2021-03-17 |
| ZA201801881B (en) | 2019-05-29 |
| WO2017035354A1 (en) | 2017-03-02 |
| CA2995997A1 (en) | 2017-03-02 |
| US20170066773A1 (en) | 2017-03-09 |
| AU2016311426B2 (en) | 2021-05-20 |
| RU2018110379A3 (https=) | 2019-12-26 |
| US20190169194A1 (en) | 2019-06-06 |
| JP6877407B2 (ja) | 2021-05-26 |
| TW201713665A (zh) | 2017-04-16 |
| CN108137607A (zh) | 2018-06-08 |
| MX2018002407A (es) | 2018-11-29 |
| HK1255330A1 (zh) | 2019-08-16 |
| EP3341374A1 (en) | 2018-07-04 |
| IL257702A (en) | 2018-04-30 |
| BR112018003588A2 (pt) | 2018-09-25 |
| US11046697B2 (en) | 2021-06-29 |
| RU2018110379A (ru) | 2019-09-27 |
| JP2018528200A (ja) | 2018-09-27 |
| CN108137607B (zh) | 2021-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR105836A1 (es) | Compuestos y composiciones útiles para tratar trastornos relacionados con ntrk | |
| AR107912A1 (es) | Inhibidores de ret | |
| AR105459A1 (es) | Derivados de pirrolo[2,1-f][1,2,4]triazina útiles para tratar trastornos relacionados con kit y pdfgr | |
| CO2022008968A2 (es) | Nuevos derivados de metilquinazolinona | |
| AR085327A1 (es) | Inhibidores del virus de la hepatitis c | |
| AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
| AR104388A1 (es) | Inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| CO6251243A2 (es) | Nuevos inhibidores macrocíclicos de la replicación del virus de hepatitis c | |
| AR099379A1 (es) | Compuestos tricíclicos como agentes antineoplásicos | |
| AR100233A1 (es) | Composición de limpieza | |
| AR106756A1 (es) | Compuestos y composiciones útiles para el tratamiento de trastornos relacionados con ntrk | |
| AR091285A1 (es) | Inhibidores de bromodominio y sus usos | |
| AR101986A1 (es) | Inhibidores de histona acetiltransferasas espirocíclicas (hat) y métodos para su uso | |
| AR098666A1 (es) | Compuestos de biarilacetamida y sus métodos de uso | |
| AR106293A1 (es) | Moduladores del receptor x farnesoide | |
| AR101815A1 (es) | Compuestos y composiciones como inhibidores de quinasa | |
| CL2019001041A1 (es) | Compuestos terapéuticos y métodos para utilizarlos. | |
| AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
| PH12017501652A1 (en) | Kv1.3 inhibitors and their medical application | |
| AR109711A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
| AR081893A1 (es) | Derivados de acido 1-(2-fluorobifenil-4-il)-alquil carboxilico para la terapia de la amiloidosis transtiretina | |
| AR110440A1 (es) | Compuestos para el tratamiento de la enfermedad respiratoria bovina o porcina | |
| MX2018011721A (es) | Compuesto de griseofulvina. | |
| CO5700776A2 (es) | Compuestos utiles para el tratamiento de enfermedades | |
| AR094804A1 (es) | Compuesto de triazinona carboxamida o su sal |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |